Arkolith/Insider Trading/RPRX/Form 4

Hite Christopher

EVP & Chairman, PartneringRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Jun 25, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8.2M
Net Open-Market Flow
-$8.2M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 23, 2026Sell(S)32K$54.11$1.8M677K
Jun 23, 2026Sell(S)118K$54.47$6.4M559K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001814238-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML